Esperion Secures Funding and Clears Debt through Royalty Deal
Company Announcements

Esperion Secures Funding and Clears Debt through Royalty Deal

An update from Esperion (ESPR) is now available.

Esperion Therapeutics, Inc. struck a deal on June 27, 2024, selling a portion of its Bempedoic Acid net sales royalties for over $304 million to OCM IP Healthcare Portfolio LP. This transaction allows the purchaser to fully recoup 1.7 times the purchase price before the royalties revert back to Esperion. Additionally, the company cleared its financial slate by repaying $343.75 million in cash to settle all outstanding Revenue Interests and related obligations, resulting in the termination of the prior agreement and release of all associated security interests.

For detailed information about ESPR stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyEsperion reports Q3 EPS (15c), consensus (18c)
Ryan AdistESPR Earnings this Week: How Will it Perform?
TheFlyEsperion says DSE reports final real-world results from MILOS German cohort
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App